Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

DA-EPOCH-R for High Grade B-Cell Lymphoma Patients with MYC and BCL2 and/or BCL6 Rearrangements: Clinical Results of the Induction Phase of the HOVON-152 Trial

Blood (2023) 142 (Supplement 1): 3090.

https://doi.org/10.1182/blood-2023-181707

Published: 2023

Journal Articles

Polyostotic DLBCL Is Characterized By a NF-Κb Pathway Affecting Molecular Profile and Superior Survival

Blood (2022) 140 (Supplement 1): 3534–3536.

https://doi.org/10.1182/blood-2022-159036

Published: 2022

Journal Articles

Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

Blood (2022) 140 (Supplement 1): 2283–2285.

https://doi.org/10.1182/blood-2022-156085

Published: 2022

Journal Articles

Consolidation Improves Survival in Primary Central Nervous System Lymphoma without Preference for Type of High-Dose Methotrexate-Based Induction Treatment Regimen

Blood (2022) 140 (Supplement 1): 369–371.

https://doi.org/10.1182/blood-2022-163244

Published: 2022

Journal Articles

Immune Profiling of Double and Triple Hit High Grade B Cell Lymphoma Patients Treated with DA-EPOCH Reveals Activation of T Cells and Reduced T Cell Exhaustion

A.Vera de Jonge, Carolien Duetz, Wassilis S.C. Bruins, Erik D. van Werkhoven, Marcel Nijland, Marjolein W.M. Van Der Poel, Koen de Heer, Clara P.W. Klerk, Yorick Sandberg, Rob Fijnheer, Pim Mutseaers, Djamila E. Issa, Lara H. Böhmer, Roel J.W. Van Kampen, Otto J. Visser, Daphne de Jong, Josée M. Zijlstra, Tuna Mutis, Martine E.D. Chamuleau

Blood (2022) 140 (Supplement 1): 9298–9299.

https://doi.org/10.1182/blood-2022-163068

Published: 2022

Journal Articles

Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study

Mirian Brink, Frederik O. Meeuwes, Marjolein W. M. van der Poel, Marie José Kersten, Mariëlle Wondergem, Pim G. N. J. Mutsaers, Lara H. Böhmer, F. J. Sherida H. Woei-A-Jin, Otto Visser, Rimke Oostvogels, Patty M. Jansen, Wouter Plattel, Gerwin A. Huls, Joost S. P. Vermaat, Marcel Nijland

Blood (2022) 140 (9): 1009–1019.

https://doi.org/10.1182/blood.2021015114

Published: 2022

Includes: Supplemental data

Journal Articles

First-Line Treatment and Survival of Stage I(E) Peripheral T-Cell Lymphoma in the Netherlands; A Nationwide Population-Based Cohort Study

Frederik O. Meeuwes, Mirian Brink, Marjolein W.M. Van Der Poel, Marie José Kersten, Mariëlle Wondergem, Pim G.N.J. Mutsaers, Lara H. Böhmer, F.J. Sherida H. Woei-a-Jin, Otto J. Visser, Rimke Oostvogels, Patty M. Jansen, Karen J. Neelis, Anne P.G. Crijns, Laurien A. Daniëls, Joost S.P. Vermaat, Gerwin A. Huls, Marcel Nijland

Blood (2021) 138 (Supplement 1): 1381.

https://doi.org/10.1182/blood-2021-148038

Published: 2021

Journal Articles

Ixazomib, Rituximab and Dexamethasone (IRD) in Patients with Relapsed or Progressive Waldenstrom's Macroblobulinemia: Results of the Prospective Phase I/II HOVON 124/Ecwm-R2 Trial

Marie José Kersten, MD PhD, Monique C. Minnema, Josephine M. Vos, MD PhD, Kazem Nasserinejad, Marcel Kap, BSc, Eftathios Kastritis, Maria Gavriatopoulou, MD, Martine E.D. Chamuleau, Dries Deeren, MD PhD, Lidwine Winnifred Tick, MD PhD, Jeanette K. Doorduijn, MD PhD, Fritz Offner, MD, Lara H Bohmer, MD, Karima Amaador, MD, Roberto D Liu, BSc, Steven T Pals, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 344.

https://doi.org/10.1182/blood-2019-122365

Published: 2019

Journal Articles

Rituximab-Pecc Induction Followed By 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or Have Failed ASCT: Results from a Phase II HOVON Study

Pieternella J Lugtenburg, MD PhD, Josée M Zijlstra, MD, Jeanette K Doorduijn, MD PhD, Lara H Böhmer, MD, Marinus van Marwijk Kooy, MD PhD, Mels Hoogendoorn, MD PhD, Henriette W Berenschot, MD, Aart Beeker, MD, Fransje Valster, MD, Harry C. Schouten, MD PhD, Marleen Luten, MSc, Henk Hofwegen, Dana A Chitu, PhD, Rolf E Brouwer, MD PhD, Gustaaf W van Imhoff, MD PhD

Blood (2015) 126 (23): 2707.

https://doi.org/10.1182/blood.V126.23.2707.2707

Published: 2015

NARROW

DA-EPOCH-R for High Grade B-Cell Lymphoma Patients with MYC and BCL2 and/or BCL6 Rearrangements: Clinical Results of the Induction Phase of the HOVON-152 Trial

Polyostotic DLBCL Is Characterized By a NF-Κb Pathway Affecting Molecular Profile and Superior Survival

Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

Consolidation Improves Survival in Primary Central Nervous System Lymphoma without Preference for Type of High-Dose Methotrexate-Based Induction Treatment Regimen

Immune Profiling of Double and Triple Hit High Grade B Cell Lymphoma Patients Treated with DA-EPOCH Reveals Activation of T Cells and Reduced T Cell Exhaustion

Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study

First-Line Treatment and Survival of Stage I(E) Peripheral T-Cell Lymphoma in the Netherlands; A Nationwide Population-Based Cohort Study

Ixazomib, Rituximab and Dexamethasone (IRD) in Patients with Relapsed or Progressive Waldenstrom's Macroblobulinemia: Results of the Prospective Phase I/II HOVON 124/Ecwm-R2 Trial

Rituximab-Pecc Induction Followed By 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or Have Failed ASCT: Results from a Phase II HOVON Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only